Literature DB >> 25503527

Bone histomorphometry in a long-term hemodialysis patient with hypoparathyroidism and sarcoidosis.

K Sumida1, Y Ubara, J Hoshino, N Hayami, T Suwabe, R Hiramatsu, E Hasegawa, M Yamanouchi, N Sawa, T Fujii, K Takaichi.   

Abstract

A bone biopsy specimen in a long-term hemodialysis patient with sarcoidosis coexisting with severe hypoparathyroidism has demonstrated that a persistent near physiological level of 1,25-dihydroxyvitamin D3 contributes to the preservation of bone remodeling and has the potential to retard the development of vascular calcification and atherosclerosis. Sarcoidosis-related hypercalcemia and hypoparathyroidism, which is characterized by 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) overproduction, is rarely seen in hemodialysis patients. Herein, we describe a 60-year-old Japanese woman on hemodialysis for 35 years who presented with malaise and hypercalcemia. Severe hypoparathyroidism without parathyroidectomy and a preserved 1,25(OH)2D3 level were detected. Computed tomography showed bilateral axillary lymphadenopathy and minimal aortic and soft tissue calcification. The axillary node biopsy led to a definite diagnosis of sarcoidosis. A bone biopsy specimen obtained from the right iliac crest showed remodeling of normal lamellar bone with scalloped cement lines and clear double labeling by tetracycline on fluorescence microscopy. Histomorphometric analysis revealed that the bone formation rate was preserved (30.0 %/year), together with a decrease of osteoid volume (5.75 %) and fibrous volume (0 %), indicating that the patient did not have adynamic bone disease and only showed mild disease. This is the first documented case of sarcoidosis-related hypercalcemia associated with severe hypoparathyroidism in a long-term hemodialysis patient who underwent bone histomorphometry. Our findings suggest that, in hemodialysis patients with sarcoidosis coexisting with severe hypoparathyroidism, a persistent near physiological level of 1,25(OH)2D3 contributes to the preservation of bone remodeling and has the potential to retard the development of vascular calcification and atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25503527     DOI: 10.1007/s00198-014-2987-8

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  36 in total

1.  Sarcoid presenting with hypercalcaemia and erythema nodosum in a haemodialysis patient.

Authors:  Susannah Barnard; Rob Marshall; Rob G Parry; Paul Johnston
Journal:  Nephrol Dial Transplant       Date:  2002-01       Impact factor: 5.992

2.  1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial.

Authors:  L R Baker; L Abrams; C J Roe; M C Faugere; P Fanti; Y Subayti; H H Malluche
Journal:  Kidney Int       Date:  1989-02       Impact factor: 10.612

3.  Tumoral calcinosis associated with hypercalcemia in a patient with chronic renal failure.

Authors:  Ryoko Horikoshi; Tetsu Akimoto; Daishi Meguro; Osamu Saito; Yasuhiro Ando; Shigeaki Muto; Eiji Kusano
Journal:  Clin Exp Nephrol       Date:  2010-10-23       Impact factor: 2.801

Review 4.  Sarcoidosis.

Authors:  Michael C Iannuzzi; Benjamin A Rybicki; Alvin S Teirstein
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

5.  Oral active vitamin D is associated with improved survival in hemodialysis patients.

Authors:  Manuel Naves-Díaz; Daniel Alvarez-Hernández; Jutta Passlick-Deetjen; Adrian Guinsburg; Cristina Marelli; Diego Rodriguez-Puyol; Jorge B Cannata-Andía
Journal:  Kidney Int       Date:  2008-07-16       Impact factor: 10.612

6.  Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis.

Authors:  A Gerakis; A J Hutchison; T Apostolou; A J Freemont; A Billis
Journal:  Nephrol Dial Transplant       Date:  1996-12       Impact factor: 5.992

7.  Significance of minimodeling in dialysis patients with adynamic bone disease.

Authors:  Yoshifumi Ubara; Tetsuo Tagami; Syohei Nakanishi; Naoki Sawa; Junichi Hoshino; Tatsuya Suwabe; Hideyuki Katori; Fumi Takemoto; Shigeko Hara; Kenmei Takaichi
Journal:  Kidney Int       Date:  2005-08       Impact factor: 10.612

Review 8.  Vitamin D control of osteoblast function and bone extracellular matrix mineralization.

Authors:  J P van Leeuwen; M van Driel; G J van den Bemd; H A Pols
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2001       Impact factor: 1.807

9.  Sarcoidosis with acute recurrent polyarthritis and hypercalcemia.

Authors:  Takeo Sato; Tsunehisa Tsuru; Kiyofumi Hagiwara; Kazuhisa Miyashita; Hiroaki Matsuno; Atsuo Goto; Masaru Oritsu; Teruhiko Hamanaka; Osamu Akiyama
Journal:  Intern Med       Date:  2006-04-17       Impact factor: 1.271

10.  Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis.

Authors:  L Brandi; H Daugaard; E Tvedegaard; T Storm; K Olgaard
Journal:  Nephron       Date:  1989       Impact factor: 2.847

View more
  1 in total

1.  Case report: Osteomalacia due to bisphosphonate treatment in a patient on hemodialysis.

Authors:  Masaki Hatano; Izuru Kitajima; Seizo Yamamoto; Masaki Nakamura; Kazuya Isawa; Yutaka Hirota; Junichi Hoshino; Naoki Sawa; Yoshifumi Ubara
Journal:  BMC Nephrol       Date:  2021-09-03       Impact factor: 2.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.